Navigation Links
Cardinal Health Reports Second Quarter Results
Date:2/5/2009

DUBLIN, Ohio, Feb. 5 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today reported solid fiscal second quarter results driven by top- and bottom-line growth from its supply chain and medical product segments.

For the quarter ended Dec. 31, 2008, revenue grew 8 percent to $25 billion, and non-GAAP earnings from continuing operations(1) increased 2 percent to $335 million. GAAP diluted earnings per share (EPS) from continuing operations declined 1 percent to $0.88. The impact of special items, impairments and other costs associated with the proposed spinoff of Clinical and Medical Products (CMP) totaled $16 million after tax or $0.05 per share, bringing non-GAAP diluted EPS from continuing operations(2) to $0.93, a 3 percent increase over the prior-year period.

"Despite a very challenging economic climate, we had solid growth from both of our primary operating segments," said R. Kerry Clark, chairman and chief executive officer of Cardinal Health. "HSCS returned to year over year segment profit growth in the second quarter, and we expect to remain on track with positive growth for the second half of the fiscal year. CMP continued its track record of double-digit segment profit growth, though we continue to see the deferral in hospital spending affecting its performance for the remainder of the fiscal year. We are reaffirming our full-year guidance, adjusted on Jan. 8, of non-GAAP EPS of $3.50 to $3.60. In addition, we remain on track to spin off the CMP businesses later this year and intend to file the Form 10 registration statement with the Securities and Exchange Commission during our fiscal third quarter."


    Q2 FY09 SUMMARY

                                 Q2 FY09            Q2 FY08          Y/Y
    Revenue                     $25.1 billion      $23.3 billion      8%

    GAAP Operating Earnings      $538 million       $519 million      4%
    Non-GAAP Operating
     Earnings(3)                 $565 million       $526 million      7%

    GAAP Earnings from
     Continuing Operations       $319 million       $325 million     (2)%
    Non-GAAP Earnings from
     Continuing Operations       $335 million       $329 million      2%

    GAAP Diluted EPS from
     Continuing Operations              $0.88              $0.89     (1)%
    Non-GAAP Diluted EPS from
     Continuing Operations              $0.93              $0.90      3%



    SECOND-QUARTER SEGMENT RESULTS

Healthcare Supply Chain Services

Healthcare Supply Chain Services increased revenue by 8 percent to $24.1 billion, driven by higher sales to existing pharmaceutical and medical supply chain customers. Sales to bulk pharmaceutical customers(4) increased 15 percent to $11 billion and sales to non-bulk pharmaceutical customers(5) increased 2 percent to $11 billion. Segment profit grew 6 percent to $333 million, primarily from an increased contribution from generic sales, inflation from branded pharmaceuticals, the increase in total segment sales volume and growth from nuclear pharmacy services. Segment profit growth was partially dampened by previously reported pharmaceutical contract re-pricings and continued disruption from anti-diversion efforts for pharmaceutical supply chain customers. During the quarter, the company resumed shipments of controlled substances from all distribution centers.

"We built upon the momentum from the first quarter and returned the segment to growth during the quarter, with solid contributions from both the pharmaceutical and medical supply chain businesses," said George Barrett, Cardinal Health vice chairman and chief executive officer of Healthcare Supply Chain Services. "In addition to the pharmaceutical distribution business, our nuclear pharmacy services and hospital supply businesses performed very well in the quarter with strong profit growth. We remain on track to achieve our goals for fiscal 2009."

    Healthcare Supply Chain Services     Q2 FY09       Q2 FY08         Y/Y

    Revenue                             $24.1 billion $22.3 billion     8%
    Segment Profit                      $333 million  $315 million      6%

Clinical and Medical Products

Revenue for Clinical and Medical Products increased 7 percent to $1.2 billion, primarily driven by organic growth from the dispensing, infusion and infection prevention businesses and the Enturia acquisition. Segment revenue was dampened by 3 percentage points due to foreign exchange rates during the quarter. Segment profit increased 16 percent to $198 million, driven by revenue growth, the Enturia acquisition and disciplined expense control. Segment profit was significantly dampened by foreign exchange rates and increased raw material costs.

"We continue to see remarkable growth from the Enturia acquisition, and continued top- and bottom-line growth in infusion and dispensing during the quarter," said David Schlotterbeck, Cardinal Health vice chairman and chief executive officer of Clinical and Medical Products. "Despite a strong second quarter, we continue to expect full-year segment profit to be flat or better because of the delay in hospital capital spending that is expected to impact the second half of our fiscal year."



    Clinical and Medical Products        Q2 FY09       Q2 FY08         Y/Y

    Revenue                             $1.2 billion  $1.1 billion      7%
    Segment Profit                      $198 million  $171 million     16%



    ADDITIONAL SECOND QUARTER AND RECENT HIGHLIGHTS:

-- Nuclear Pharmacy Services signed new, long-term supply agreements with Lantheus Medical Imaging and GE Healthcare to ensure continued and broadened access to their portfolio of products including Cardiolite(R), Myoview(TM) and other proprietary products.

-- Announced a five-year supply and co-marketing agreement with SRI Surgical(R) to offer surgical kits that include disposable health care products from Cardinal Health and reusable health care products from SRI Surgical(R).

-- Awarded one of the largest infusion contracts in company history that will provide 8,000 IV channels to Sutter Health, a leading not-for-profit network of community-based health care providers in Northern California.

-- Launched the Pyxis(R) MedStation(R) 4000 automated medication dispensing system that offers new features to help hospitals increase the security of high-alert medications and reduce medication errors.

-- Introduced an industry-first Performance Analytics Service that provides hospitals with customized, actionable recommendations to help improve medication safety.

CONFERENCE CALL

Cardinal Health will host a conference call and webcast today at 8:30 a.m. EST to discuss second quarter results. To access the call and corresponding slide presentation, visit the investor page at cardinalhealth.com or dial 617.213.4845, passcode 86908096. Presentation slides, an audio replay and a transcript will be archived on the Web site after the conclusion of the meeting. The audio replay will also be available until 11 p.m. EST on Feb. 7 by dialing 617.801.6888, passcode 38752008.

UPCOMING EVENTS

George Barrett, Cardinal Health vice chairman and chief executive officer of Healthcare Supply Chain Services, will address investors at the UBS Global Healthcare Services Conference in New York on Feb. 9 at 10 a.m. EST. Barrett will also address investors at the Barclays Capital Global Healthcare Conference in Miami on March 11. He will discuss Cardinal Health's diverse products and services, company performance and strategies for growth at both conferences. For more details or to access the live webcasts or transcripts of his remarks, go to the investors page at cardinalhealth.com.

On June 2, Cardinal Health will be hosting its annual analyst and investor day. This year's format will feature two separate sessions, one dedicated to Cardinal Health and the second covering the businesses included in the proposed spinoff of Clinical and Medical Products. More information, including webcast details, will be posted on the investor page at cardinalhealth.com.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) electronic infection surveillance service, VIASYS(R) respiratory care products and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at www.cardinalhealth.com.

(1) Non-GAAP earnings from continuing operations: Earnings from continuing operations excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) spin-off costs not included in special items or impairments, (gain)/loss on sale of assets and other, net, each net of tax.

(2) Non-GAAP diluted EPS from continuing operations: Non-GAAP earnings from continuing operations divided by diluted weighted average shares outstanding.

(3) Non-GAAP operating earnings: Operating earnings excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) spin-off costs not included in special items or impairments, (gain)/loss on sale of assets and other, net.

(4) Bulk pharmaceutical customers consist of Healthcare Supply Chain Services customers to which the segment distributes pharmaceutical, radiopharmaceutical and over-the-counter health care products to the customers' centralized warehouse operations and mail order businesses.

(5) Non-bulk pharmaceutical customers consist of all Healthcare Supply Chain Services customers to which the segment distributes pharmaceutical, radiopharmaceutical and over-the-counter health care products other than bulk customers.

A reconciliation of the differences between these non-GAAP financial measures and their most directly comparable GAAP financial measures is provided in the attached tables and at www.cardinalhealth.com.

Cardinal Health uses its Web site as a channel of distribution for material company information. Important information, including news releases, analyst presentations and financial information regarding Cardinal Health is routinely posted and accessible on the investor page at www.cardinalhealth.com.

This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: uncertainties related to the deferral in hospital capital spending affecting Cardinal Health's Clinical and Medical Products segment and difficulties in forecasting the exact duration and potential long-term changes in hospital spending patterns; uncertainties regarding the planned spinoff of the clinical and medical products businesses as a new stand-alone entity, including the timing and terms of any such spinoff and whether such spinoff will be completed, and uncertainties regarding the impact of the planned spinoff on Cardinal Health, the new clinical and medical products company and the potential market for their respective securities; competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; uncertainties relating to timing of generic and branded pharmaceutical introductions and the frequency or rate of branded pharmaceutical price appreciation or generic pharmaceutical price deflation; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal or administrative proceedings; future actions of regulatory bodies or government authorities relating to Cardinal Health's manufacturing or sale of products and other costs or claims that could arise from its manufacturing, compounding or repackaging operations or from its other services; the costs, difficulties and uncertainties related to the integration of acquired businesses; uncertainties related to the recent disruptions in the financial markets, including uncertainties related to the availability and/or cost of credit for Cardinal Health; the potential impact on Cardinal Health's customers and vendors of declining economic conditions, which could impact Cardinal Health's earnings and cash flow; and conditions in the pharmaceutical market and general economic and market conditions. This news release reflects management's views as of Feb. 5, 2009. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.



                     CARDINAL HEALTH, INC. AND SUBSIDIARIES
            CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)

                                                Second Quarter
    (in millions, except per Common
     Share amounts)                           2009          2008    % Change

    Revenue                                 $25,099.5     $23,282.7      8 %
    Cost of products sold                    23,683.1      21,928.1      8 %
    Gross margin                              1,416.4       1,354.6      5 %

    Selling, general and administrative
     expenses                                   851.9         828.9      3 %
    Impairments, (gain)/loss on sale of
     assets and other, net                        6.9         (23.0)     N.M.

    Special items:
      Restructuring charges                      14.2          31.5      N.M.
      Acquisition integration charges             5.8          10.0      N.M.
      Litigation and other                       (0.3)        (12.0)     N.M.
    Operating earnings                          537.9         519.2      4 %

    Interest expense and other                   62.4          50.0     25 %
    Earnings before income taxes and
     discontinued operations                    475.5         469.2      1 %

    Provision for income taxes                  156.6         144.1      9 %
    Earnings from continuing operations         318.9         325.1     (2)%

    Loss from discontinued operations (net of
     tax expense of $2.4 and $0.7 for the
     second quarter of fiscal 2009 and
     2008, respectively)                         (2.4)         (0.4)     N.M.

    Net earnings                               $316.5        $324.7     (3)%


    Basic earnings per Common Share:
    Continuing operations                       $0.89         $0.91     (2)%
    Discontinued operations                       -             -        N.M.
      Net basic earnings per Common Share       $0.89         $0.91     (2)%

    Diluted earnings per Common Share:
    Continuing operations                       $0.88         $0.89     (1)%
    Discontinued operations                       -             -        N.M.
      Net diluted earnings per Common
       Share                                    $0.88         $0.89     (1)%

    Weighted average number of Common
     Shares outstanding:
    Basic                                       357.3         358.7
    Diluted                                     360.3         364.6



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
            CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)

                                                  Year-to-Date
    (in millions, except per Common
     Share amounts)                            2009          2008     % Change

    Revenue                                 $49,446.7     $45,256.1       9 %
    Cost of products sold                    46,665.8      42,559.3      10 %
    Gross margin                              2,780.9       2,696.8       3 %

    Selling, general and administrative
     expenses                                 1,734.1       1,659.0       5 %
    Impairments, (gain)/loss on sale of
     assets and other, net                       10.5         (23.2)      N.M.

    Special items:
      Restructuring charges                      63.9          46.2       N.M.
      Acquisition integration charges             8.2          15.5       N.M.
      Litigation and other                         -           (9.7)      N.M.
    Operating earnings                          964.2       1,009.0      (4)%

    Interest expense and other                  124.8          92.9      34 %
    Earnings before income taxes and
     discontinued operations                    839.4         916.1      (8)%

    Provision for income taxes                  270.7         287.8      (6)%
    Earnings from continuing operations         568.7         628.3      (9)%

    Loss from discontinued operations (net of
     tax expense of $3.0 and $2.7 for fiscal
     2009 and 2008 year-to-date, respectively)   (3.1)         (1.8)      N.M.

    Net earnings                               $565.6        $626.5     (10)%


    Basic earnings / (loss) per Common
     Share:
    Continuing operations                       $1.59         $1.74      (9)%
    Discontinued operations                     (0.01)          -         N.M.
      Net basic earnings per Common Share       $1.58         $1.74      (9)%

    Diluted earnings / (loss) per Common
     Share:
    Continuing operations                       $1.57         $1.71      (8)%
    Discontinued operations                       -           (0.01)      N.M.
      Net diluted earnings per Common
       Share                                    $1.57         $1.70      (8)%

    Weighted average number of Common
     Shares outstanding:
    Basic                                       357.0         360.8
    Diluted                                     361.2         367.8



                     CARDINAL HEALTH, INC. AND SUBSIDIARIES
                CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

                                                  December 31,        June 30,
    (in millions)                                     2008              2008

    Assets
    Cash and equivalents                            $772.6          $1,291.3
    Trade receivables, net                         5,215.3           5,006.9
    Current portion of net investment in
     sales-type leases                               388.8             383.7
    Inventories                                    8,535.8           6,768.8
    Prepaid expenses and other                       624.1             593.1
    Assets held for sale                                -              140.4
      Total current assets                        15,536.6          14,184.2

    Property and equipment, net                    1,729.6           1,737.2
    Net investment in sales-type leases,
     less current portion                            946.6             916.8
    Goodwill and other intangibles, net            6,183.0           6,225.9
    Other assets                                     619.0             384.1
      Total assets                               $25,014.8         $23,448.2


    Liabilities and Shareholders' Equity
    Current portion of long-term
     obligations and other short-term
     borrowings                                     $467.4            $159.0
    Accounts payable                               9,666.2           8,311.8
    Other accrued liabilities                      1,503.0           1,889.7
    Liabilities from businesses held for
     sale and discontinued operations                  2.4              15.4
      Total current liabilities                   11,639.0          10,375.9

    Long-term obligations, less current
     portion and other short-term borrowings       3,389.2           3,687.4
    Deferred income taxes and other liabilities    1,858.7           1,637.4
      Total shareholders' equity                   8,127.9           7,747.5
      Total liabilities and shareholders'
       equity                                    $25,014.8         $23,448.2



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
            CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

                                           Second Quarter       Year-to-Date
    (in millions)                          2009      2008      2009      2008

    Cash Flows From Operating
     Activities:
    Net earnings                         $316.5    $324.7    $565.6    $626.5
    Loss from discontinued operations       2.4       0.4       3.1       1.8
      Earnings from continuing
       operations                         318.9     325.1     568.7     628.3
    Adjustments to reconcile earnings
     from continuing operations to net
     cash provided by / (used in)
     operating activities:
      Depreciation and amortization        99.5      97.0     200.5     191.9
      Asset impairments and (gain)/loss
       on sale of assets, net               6.9     (23.0)     10.5     (23.2)
      Equity compensation                  34.8      28.4      59.2      54.5
      Provision for bad debts              14.2       5.3      26.8      10.4
    Change in operating assets and
     liabilities, net of effects from
     acquisitions:
      (Increase) / decrease in trade
       receivables                        628.9      41.3    (153.5)   (150.6)
      Increase in inventories            (844.5)   (486.0) (1,718.2)   (253.6)
      Increase in net investment in
       sales-type leases                  (14.8)    (34.5)    (35.0)    (58.6)
      Increase / (decrease) in accounts
       payable                            312.9    (116.7)  1,295.5    (179.9)
      Other accrued liabilities and
       operating items, net              (282.9)    139.0    (332.6)    195.9
        Net cash provided by / (used in)
         operating activities -
         continuing operations            273.9     (24.1)    (78.1)    415.1
        Net cash used in operating
         activities - discontinued
         operations                        (2.4)     (2.0)     (3.2)    (32.5)
    Net cash provided by / (used in)
     operating activities                 271.5     (26.1)    (81.3)    382.6

    Cash Flows From Investing
     Activities:
    Acquisition of subsidiaries, net of
     divestitures and cash acquired          -       48.9      (6.2)    (39.2)
    Proceeds from sale of property and
     equipment                             11.3       4.9      12.3       7.4
    Additions to property and equipment   (92.6)    (80.6)   (182.2)   (172.1)
    Sale of investment securities
     available for sale, net                 -         -         -      131.9
      Net cash used in investing
       activities - continuing
       operations                         (81.3)    (26.8)   (176.1)    (72.0)
      Net cash used in investing
       activities - discontinued
       operations                            -         -         -         -
    Net cash used in investing
     activities                           (81.3)    (26.8)   (176.1)    (72.0)

    Cash Flows From Financing
     Activities:
    Net change in commercial paper and
     short-term borrowings                100.0     287.4     101.1     519.4
    Reduction of long-term obligations   (154.5)     (1.2)   (307.1)    (14.1)
    Proceeds from long-term
     obligations, net of issuance costs    13.2       1.0      21.7       1.0
    Proceeds from issuance of Common
     Shares                                 2.8      58.9      20.7     164.4
    Tax benefits from exercises of
     stock options                         (1.1)      2.4       2.3      14.0
    Dividends on Common Shares            (50.2)    (43.5)   (100.0)    (87.7)
    Purchase of Common Shares in
     treasury                                -     (357.3)       -   (1,032.0)
      Net cash used in financing
       activities - continuing
       operations                         (89.8)    (52.3)   (261.3)   (435.0)
      Net cash used in financing
       activities - discontinued
       operations                            -         -         -         -
    Net cash used in financing
     activities                           (89.8)    (52.3)   (261.3)   (435.0)

    Net increase / (decrease) in cash
     and equivalents                      100.4    (105.2)   (518.7)   (124.4)

    Cash and equivalents at beginning
     of period                            672.2   1,289.6   1,291.3   1,308.8

    Cash and equivalents at end of
     period                              $772.6  $1,184.4    $772.6  $1,184.4



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
                                 BUSINESS ANALYSIS

                                   TOTAL COMPANY
                                                              Non-GAAP
                                          Second Quarter   Second Quarter (1)
    (in millions)                         2009     2008     2009    2008

    Revenue
    Amount                              $25,100  $23,283
    Growth Rate                             8 %      7 %

    Operating Earnings
    Amount                                 $538     $519    $565    $526
    Growth Rate                             4 %      1 %     7 %    (3)%

    Earnings from Continuing Operations
    Amount                                 $319     $325    $335    $329
    Growth Rate                            (2)%      3 %     2 %    (3)%

                                                              Non-GAAP
                                           Year-to-Date    Year-to-Date (1)
                                          2009     2008     2009    2008

    Revenue
    Amount                              $49,447  $45,256
    Growth Rate                             9 %      6 %

    Operating Earnings
    Amount                                 $964   $1,009  $1,047  $1,038
    Growth Rate                            (4)%      5 %     1 %     2 %

    Earnings from Continuing Operations
    Amount                                 $569     $628    $603    $647
    Growth Rate                            (9)%      4 %    (7)%      -

Refer to the GAAP / Non-GAAP Reconciliation for definitions and calculations supporting the non-GAAP balances.

    (1) See definitions for explanation of a change in the method of
        calculating these financial measures from prior quarters.



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
                             SEGMENT BUSINESS ANALYSIS

                          Second Quarter                      Second Quarter
    (in millions)         2009     2008   (in millions)        2009     2008

    HEALTHCARE SUPPLY
     CHAIN SERVICES                       CLINICAL AND MEDICAL PRODUCTS

    Revenue (1)                           Revenue (1)
    Amount             $24,096  $22,346   Amount             $1,215   $1,133
    Growth Rate            8 %      6 %   Growth Rate           7 %     31 %
    Mix                   94 %     94 %   Mix                   5 %      5 %

    Segment Profit (2)                    Segment Profit (2)
    Amount                $333     $315   Amount               $198     $171
    Growth Rate            6 %    (20)%   Growth Rate          16 %     35 %
    Mix                   59 %     62 %   Mix                  35 %     33 %
    Segment Profit                        Segment Profit
     Margin             1.38 %   1.41 %    Margin           16.33 %  15.06 %



                         Second Quarter
    (in millions)         2009     2008

    ALL OTHER

    Revenue (1)
    Amount                $265     $301
    Growth Rate            (12)%      2%
    Mix                      1%       1%

    Segment Profit (2)
    Amount                 $31      $25
    Growth Rate             25%     (10)%
    Mix                      6%       5%
    Segment Profit
     Margin              11.61%    8.19%


    Refer to definitions for an explanation of calculations.

(1) Total consolidated revenue for the three months ended December 31, 2008 was $25.1 billion, which included total segment revenue of $25.6 billion and Corporate revenue of $(0.5) billion. Total consolidated revenue for the three months ended December 31, 2007 was $23.3 billion, which included total segment revenue of $23.8 billion and Corporate revenue of $(0.5) billion. Corporate consists primarily of elimination of inter-segment revenue.

(2) Total consolidated operating earnings for the three months ended December 31, 2008 were $538 million, which included total segment profit of $562 million and Corporate loss of $(24) million. Total consolidated operating earnings for the three months ended December 31, 2007 were $519 million, which included total segment profit of $511 million and Corporate profit of $8 million. Corporate includes, among other things, special items and impairments, (gain)/loss on sale of assets and other, net.



                       CARDINAL HEALTH, INC. AND SUBSIDIARIES
                             SEGMENT BUSINESS ANALYSIS


                            Year-to-Date                       Year-to-Date
    (in millions)          2009     2008  (in millions)        2009     2008

    HEALTHCARE SUPPLY
     CHAIN SERVICES                       CLINICAL AND MEDICAL PRODUCTS

    Revenue (1)                           Revenue (1)
    Amount              $47,515  $43,439  Amount             $2,369   $2,165
    Growth Rate             9%       5%   Growth Rate           9%      32%
    Mix                     94%      94%  Mix                   5%       5%

    Segment Profit (2)                    Segment Profit (2)
    Amount                 $625     $662  Amount               $365     $316
    Growth Rate            (6)%     (9)%  Growth Rate          16%      49%
    Mix                    60%     65%    Mix                  35%      31%
    Segment Profit                        Segment Profit
     Margin               1.32%    1.52%   Margin            15.40%   14.58%



                            Year-to-Date
    (in millions)          2009     2008

    ALL OTHER

    Revenue (1)
    Amount                 $538     $595
    Growth Rate             (10)%      3%
    Mix                       1%       1%

    Segment Profit (2)
    Amount                  $55      $47
    Growth Rate              16%     (16)%
    Mix                       5%       4%
    Segment Profit
     Margin               10.16%    7.91%



    Refer to definitions for an explanation of calculations.

(1) Total consolidated revenue for the six months ended December 31, 2008 was $49.4 billion, which included total segment revenue of $50.4 billion and Corporate revenue of $(1.0) billion. Total consolidated revenue for the six months ended December 31, 2007 was $45.3 billion, which included total segment revenue of $46.2 billion and Corporate revenue of $(0.9) billion. Corporate consists primarily of elimination of inter-segment revenue.

(2) Total consolidated operating earnings for the six months ended December 31, 2008 were $964 million, which included total segment profit of $1,045 million and Corporate loss of $(81) million. Total consolidated operating earnings for the six months ended December 31, 2007 were $1,009 million, which included total segment profit of $1,025 million and Corporate loss of $(16) million. Corporate includes, among other things, special items and impairments, (gain)/loss on sale of assets and other, net.



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
                            SCHEDULE OF NOTABLE ITEMS

                                           Second Quarter    Year-to-Date
     (in millions, except per Common
      Share amounts)                      2009       2008    2009    2008


    Special Items
    Restructuring charges               $(14.2)    $(31.5) $(63.9) $(46.2)
    Acquisition integration charges       (5.8)     (10.0)   (8.2)  (15.5)
    Litigation and other                   0.3       12.0      -      9.7
      Total special items                (19.7)     (29.5)  (72.1)  (52.0)
      Tax benefit                          7.2       11.2    24.4    18.9
      Special items, net of tax         $(12.5)    $(18.3) $(47.7) $(33.1)

      Decrease to diluted EPS from
       continuing operations            $(0.04)    $(0.05) $(0.13) $(0.09)


    Other Spin-Off Costs
    Other Spin-Off Costs                 $(0.4)    $  -    $ (0.4) $   -
      Tax benefit                          0.2        -       0.2      -
      Other Spin-Off Costs, net of tax   $(0.2)    $  -    $ (0.2) $   -

      Increase to diluted EPS from
       continuing operations             $  -      $  -    $    -   $   -


    Impairments, Gain/(Loss) on Sale
     of Assets and Other, Net
    Impairments, gain/(loss) on sale
     of assets and other, net            $(6.9)     $23.0  $(10.5) $ 23.2
      Tax benefit / (expense)              3.4       (8.8)   24.2    (8.9)
      Impairments, gain/(loss) on sale
       of assets and other, net, net of
       tax                               $(3.5)     $14.2   $13.7   $14.3

      Increase / (decrease) to diluted
       EPS from continuing operations   $(0.01)     $0.04   $0.03   $0.04


    Weighted Average Number of Diluted
     Shares Outstanding                  360.3      364.6   361.2   367.8



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
                            ASSET MANAGEMENT ANALYSIS

                                        Second Quarter     Year-to-Date
                                        2009     2008      2009     2008


    Receivable Days                     18.7     20.2
    Days Inventory on Hand                29       28


    Debt to Total Capital                32%      36%
    Net Debt to Capital                  28%      29%


    Return on Equity                     15.8%    18.3%    14.3%    17.4%
    Non-GAAP Return on Equity (1)        16.6%    18.6%    15.1%    18.0%


    Return on Invested Capital           7.36%    7.70%    6.69%    7.42%
    Non-GAAP Return on Invested
     Capital 1                           7.69%    7.79%    7.04%    7.63%


    Effective Tax Rate from Continuing
     Operations                          33.0%    30.7%    32.3%    31.4%
    Non-GAAP Effective Tax Rate from
     Continuing Operations (1)           33.3%    30.8%    34.6%    31.5%



    Refer to the GAAP / Non-GAAP Reconciliation for non-GAAP calculations.

    (1) See definitions for explanation of a change in the method of
        calculating these financial measures from prior quarters.



                     CARDINAL HEALTH, INC. AND SUBSIDIARIES
                         GAAP / NON-GAAP RECONCILIATION

                                             Second Quarter 2009

                                                       Impairments,
                                                       (Gain)/Loss
                                                         on Sale
                                                Other   of Assets
    (in millions, except per          Special Spin-Off  and Other,
     Common Share amounts)      GAAP   Items    Costs      Net     Non-GAAP(1)

    Operating Earnings
    Amount                      $538    $20      -         $7         $565
    Growth Rate                    4%                                    7%

    Provision for Income Taxes  $157     $7      -         $3         $167

    Earnings from Continuing
     Operations
    Amount                      $319    $13      -         $4         $335
    Growth Rate                   (2)%                                   2%

    Diluted EPS from
     Continuing Operations
    Amount                     $0.88   $0.04     -      $0.01        $0.93
    Growth Rate                   (1)%                                   3%



                                             Year-to-Date 2009

                                                       Impairments,
                                                       (Gain)/Loss
                                                         on Sale
                                                Other   of Assets
    (in millions, except per          Special Spin-Off  and Other,
     Common Share amounts)      GAAP   Items    Costs      Net     Non-GAAP(1)

     Operating Earnings
     Amount                     $964    $72      -        $10        $1,047
     Growth Rate                  (4)%                                    1%

     Provision for Income
      Taxes                      271    $24      -        $24          $320

     Earnings from Continuing
      Operations
     Amount                     $569    $48      -       ($14)         $603
     Growth Rate                  (9)%                                   (7)%

     Diluted EPS from
      Continuing Operations
     Amount                    $1.57  $0.13      -     ($0.03)        $1.67
     Growth Rate                  (8)%                                   (5)%



                                             Second Quarter 2008

                                                      Impairments,
                                                       (Gain)/Loss
                                                         on Sale
                                                Other   of Assets
    (in millions, except per          Special Spin-Off  and Other,
     Common Share amounts)      GAAP   Items    Costs      Net     Non-GAAP(1)

    Operating Earnings
    Amount                      $519    $30      -       ($23)       $526
    Growth Rate                    1%                                  (3)%

    Provision for Income Taxes  $144    $11      -        ($9)       $147

    Earnings from Continuing
     Operations
    Amount                      $325    $18      -       ($14)       $329
    Growth Rate                    3%                                  (3)%

    Diluted EPS from
     Continuing Operations
    Amount                     $0.89  $0.05      -      $0.04)      $0.90
    Growth Rate                   16%                                   8%



                                             Year-to-Date 2008

                                                      Impairments,
                                                       (Gain)/Loss
                                                         on Sale
                                                Other   of Assets
    (in millions, except per          Special Spin-Off  and Other,
     Common Share amounts)      GAAP   Items    Costs      Net     Non-GAAP(1)



    Operating Earnings
    Amount                    $1,009    $52      -       ($23)     $1,038
    Growth Rate                  5 %                                    2 %

    Provisions for Income Taxes $288    $19      -        ($9)       $298

    Earnings from Continuing
     Operations
    Amount                      $628    $33      -       ($14)       $647
    Growth Rate                  4 %                                    -

    Diluted EPS from
     Continuing Operations
    Amount                     $1.71  $0.09      -     ($0.04)      $1.76
    Growth Rate                  16%                                  12%


    The sum of the components may not equal the total due to rounding

   (1) See definitions for explanation of a change in the method of
       calculating these financial measures from prior quarters.


                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
                          GAAP / NON-GAAP RECONCILIATION

                                   Second Quarter          Year-to-Date
    (in millions)                  2009      2008        2009       2008


    GAAP Return on Equity          15.8%      18.3%      14.3%     17.4%

    Non-GAAP Return on
     Equity
    Net earnings                 $316.5     $324.7     $565.6    $626.5
    Special items, net of
     tax, in continuing
     operations                    12.5       18.3       47.7      33.1
    Other Spin-Off Costs,
     net of tax                     0.2         -         0.2        -
    Impairments, (gain)/loss
     on sale of assets and
     other, net, net of
     tax, in continuing
     operations                     3.5      (14.2)     (13.8)    (14.3)
      Adjusted net earnings      $332.7     $328.8     $599.7    $645.3

      Annualized               $1,330.8   $1,315.2   $1,199.4  $1,290.6

      Divided by average
       shareholders'
       equity (1)              $8,023.0   $7,088.2   $7,931.2  $7,184.4

    Non-GAAP return on
     equity (2)                    16.6%      18.6%      15.1%     18.0%



                                   Second Quarter         Year-to-Date
                                   2009      2008        2009       2008

    GAAP Return on Invested
     Capital                       7.36%      7.70%      6.69%      7.42%

    Non-GAAP Return on
     Invested Capital
    Net earnings                 $316.5     $324.7     $565.6     $626.5
    Special items, net of
     tax, in continuing
     operations                    12.5       18.3       47.7       33.1
    Other Spin-Off Costs,
     net of tax                     0.2         -         0.2         -
    Impairments, (gain)/loss
     on sale of assets and
     other, net, net of
     tax, in continuing
     operations                     3.5      (14.2)     (13.8)     (14.3)
    Interest expense and
     other, net of tax             39.9       32.0       79.8       59.4
      Adjusted net earnings      $372.6     $360.8     $679.5     $704.7

    Annualized                 $1,490.4   $1,443.2   $1,359.0   $1,409.4

    Divided by average total
     invested capital (3)     $19,372.5  $18,529.9  $19,292.8  $18,483.2


    Non-GAAP return on
     invested capital (2)          7.69%      7.79%      7.04%      7.63%

(1) The average shareholders' equity shown above is calculated using the average of the prior and current quarters except for year-to-date which is calculated as the average of shareholders' equity at the end of the prior years' fourth quarter plus each of the current year quarters.

(2) See definitions for explanation of a change in the method of calculating these financial measures from prior quarters.

(3) Total invested capital is calculated as the sum of the current portion of long-term obligations and other short-term borrowings, long-term obligations, total shareholders' equity and unrecorded goodwill. The average total invested capital is calculated using the average of total invested capital at the end of the prior and current quarters except for year-to-date which is calculated as the average of the prior years' fourth quarter plus each of the current year quarters. Unrecorded goodwill is $7.5 billion for all periods presented.



                      CARDINAL HEALTH, INC. AND SUBSIDIARIES
                          GAAP / NON-GAAP RECONCILIATION

                                            Second Quarter     Year-to-Date
    (in millions)                            2009      2008    2009    2008


    GAAP Effective Tax Rate from
     Continuing Operations                   33.0%     30.7%   32.3%   31.4%

    Non-GAAP Effective Tax Rate from
     Continuing Operations
    Earnings before income taxes and
     discontinued operations               $475.5    $469.2  $839.4  $916.1
    Special items                            19.7      29.5    72.1    52.0
    Other Spin-Off Costs                      0.4        -      0.4      -
    Impairments, (gain)/loss on sale of
     assets and other, net                    6.9     (23.0)   10.5   (23.2)
      Adjusted earnings before income
       taxes and discontinued
       operations                          $502.5    $475.7  $922.4  $944.9

    Provision for income taxes             $156.6    $144.1  $270.7  $287.8
    Special items tax benefit                 7.2      11.2    24.4    18.9
    Other Spin-Off Costs tax benefit          0.2        -      0.2      -
    Impairments, (gain)/loss on sale of
     assets and other, net, tax impact        3.4      (8.8)   24.3    (8.9)
      Adjusted provision for income
       taxes                               $167.4    $146.5  $319.6  $297.8

    Non-GAAP effective tax rate from
     continuing operations (1)               33.3%     30.8%   34.6%   31.5%


                                             Second Quarter
                                             2009      2008


    Debt to Total Capital                      32%       36%

    Net Debt to Capital
    Current portion of long-term
     obligations and other short-term
     borrowings                            $467.4    $673.6
    Long-term obligations, less current
     portion and other short-term
     borrowings                           3,389.2   3,396.5
      Debt                               $3,856.6  $4,070.1
    Cash and equivalents                   (772.6) (1,184.4)
      Net debt                           $3,084.0  $2,885.7
    Total shareholders' equity           $8,127.9  $7,108.1
    Capital                             $11,211.9  $9,993.8
      Net debt to capital                      28%       29%

Forward-Looking Non-GAAP Financial Measures

The Company presents non-GAAP earnings from continuing operations and non- GAAP effective tax rate from continuing operations (and presentations derived from these financial measures) on a forward- looking basis. The most directly comparable forward-looking GAAP measures are earnings from continuing operations and effective tax rate from continuing operations. The Company is unable to provide a quantitative reconciliation of these forward-looking non- GAAP measures to the most comparable forward-looking GAAP measures because the Company cannot reliably forecast special items, impairments, (gain)/loss on sale of assets and other, net and Other Spin-Off Costs, which are difficult to predict and estimate and are primarily dependent on future events. Please note

that the unavailable reconciling items could significantly impact the Company's future financial results.

(1) See definitions for explanation of a change in the method of calculating this financial measure from prior quarters.



    CARDINAL HEALTH, INC. AND SUBSIDIARIES
    DEFINITIONS

    GAAP
    Debt:  long-term obligations plus short-term borrowings

Debt to Total Capital: debt divided by (debt plus total shareholders' equity)

Diluted EPS from Continuing Operations: earnings from continuing operations divided by diluted weighted average shares outstanding

Effective Tax Rate from Continuing Operations: provision for income taxes divided by earnings before income taxes and discontinued operations

Operating Cash Flow: net cash provided by / (used in) operating activities from continuing operations

Other Spin-Off Costs: costs incurred in connection with the Company's plans to spin off most of its clinical and medical products businesses that are not included in special items or impairments, (gain)/loss on sale of assets and other, net

Segment Profit: segment revenue minus (segment cost of products sold and segment selling, general and administrative expenses)

Segment Profit Margin: segment profit divided by segment revenue

Segment Profit Mix: segment profit divided by total segment profit for all segments

Return on Equity: annualized net earnings divided by average shareholders' equity

Return on Invested Capital: annualized net earnings plus interest expense and other divided by (average total shareholders' equity plus debt plus unrecorded goodwill)

Revenue Mix: segment revenue divided by total segment revenue for all segments

NON-GAAP

Net Debt to Capital: net debt divided by (net debt plus total shareholders' equity)

Net Debt: debt minus (cash and equivalents and short-term investments available for sale)

Non-GAAP Diluted EPS from Continuing Operations: non-GAAP earnings from continuing operations divided by diluted weighted average shares outstanding (1)

Non-GAAP Diluted EPS from Continuing Operations Growth Rate: (current period non-GAAP diluted EPS from continuing operations minus prior period non- GAAP diluted EPS from continuing operations) divided by prior period non-GAAP diluted EPS from continuing operations (1)

Non-GAAP Earnings from Continuing Operations: earnings from continuing operations excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) Other Spin-Off Costs, each net of tax (1)

Non-GAAP Earnings from Continuing Operations Growth Rate: (current period non-GAAP earnings from continuing operations minus prior period non-GAAP earnings from continuing operations) divided by prior period non-GAAP earnings from continuing operations (1)

Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) Other Spin-Off Costs) divided by (earnings before income taxes and discontinued operations adjusted for (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) Other Spin-Off Costs) (1)

Non-GAAP Operating Earnings: operating earnings excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) Other Spin-Off Costs (1)

Non-GAAP Operating Earnings Growth Rate: (current period non-GAAP operating earnings minus prior period non-GAAP operating earnings) divided by prior period non-GAAP operating earnings (1)

Non-GAAP Return on Equity: (annualized current period net earnings excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) Other Spin-Off Costs, each net of tax) divided by average shareholders' equity (1)

Non-GAAP Return on Invested Capital: (annualized net earnings excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net, (3) Other Spin-Off Costs and (4) interest expense and other, each net of tax) divided by (average total shareholders' equity plus debt plus unrecorded goodwill) (1)

(1) During the second quarter of fiscal 2009, the Company began to exclude Other Spin-Off Costs from the calculation of this non-GAAP financial measure. Prior year results have been recast to reflect the new calculation methodology.


'/>"/>
SOURCE Cardinal Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Cardinal Health Updates FY09 Outlook
2. Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits
3. Cardinal Health Announces Preliminary Shareholder Voting Results at Annual Meeting
4. Cardinal Health Reports First Quarter Results
5. Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health
6. Cardinal Health Reports Fiscal 2008 Results, Provides Fiscal 2009 Outlook
7. Cardinal Health Declares Regular Quarterly Dividend
8. Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts
9. Cardinal Health Formalizes Consolidation of Businesses Into Two Primary Operating and Reporting Segments
10. Cardinal Health Increases Quarterly Dividend by 17 Percent
11. Cardinal Health Reports Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... , ... Multiple award winning plumbing company in San Diego, Bill ... core values of exceptional customer service, quality work at reasonable rates, and giving back ... San Diego plumbing, and other services including heating & air conditioning and restoration & ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... of Sovaldi, which made headlines mostly for its cost despite its potential to ... moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have created ...
(Date:5/6/2016)... ... May 06, 2016 , ... This Mother’s Day kicks off the start of ... National Women’s Health Week takes place May 8-May 14. , Throughout the ... to empower women to make their health a top priority. Women everywhere are being ...
(Date:5/6/2016)... ... May 06, 2016 , ... “ Crossing Over: Affirmations of Faith in the ... who have allowed those holding vigil to glimpse into the supernatural as their lives ... help readers spiritually and practically gain insight into providing care to terminal patients. ...
(Date:5/5/2016)... Aliso Viejo, CA (PRWEB) , ... May 05, 2016 , ... ... use in Final Cut Pro X. Drag and drop a TransWipe preset between two ... project. Choose from smooth corner wipes to colored panels with customizable color and orientation ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
(Date:5/3/2016)... May 4, 2016 Research and ... Cancer Stem Cell Therapy Market Outlook 2020" report ... ) , ,Recombinant technology has improved significantly in ... to be developed in coming years. Many cancer drugs ... stem cell therapies are also expected to be developed ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
Breaking Medicine Technology: